Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dCzeCfbwocevnTbtGhEp

  ADVERTISEMENT  
April 26, 2012
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNM SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNM prior to publication. Questions and comments may be directed to SmartBrief at snm@smartbrief.com.

  Top Story 
 
  • Study: FDG-PET scans may lead to misdiagnosis of Alzheimer's
    Sixty-five percent of patients in a community setting had a misdiagnosis or inconclusive data after an FDG-PET scan for Alzheimer's disease, with 35% having false-positive results, according to a study presented at a neurology meeting. The study indicates a need to standardize protocols for reading results, an expert said. Another expert has expressed concern over the findings, particularly with the arrival of new PET tracers for Alzheimer's. Medscape (free registration) (4/25) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
“There have been some patients who have come to our facility because they know we have Intego and that we care about radiation dose reduction.” – Joseph A. Kmiecik, MD, PhD, Radiologist and Radiation Safety Officer at KishHealth System. To hear the full video testimonial about Intego’s impact at Kishwaukee Community Hospital, click here.

  Clinical News & Research 
 
  • Novelos touts promising initial results for agent LIGHT
    Novelos Therapeutics said the University of Wisconsin Carbone Cancer Center has finished the first cohort in a Phase I/II trial involving I-124-CLR1404, its PET imaging agent for cancer that is being tested on patients with advanced non-small cell lung cancer. Initial study results indicate the agent, also called LIGHT, can identify tumors more accurately than 18F-fluorodeoxyglucose, a researcher said. Yahoo!/PR Newswire/News release (4/24) LinkedInFacebookTwitterEmail this Story
Aflac now offers packages for brokers like you that help maximize revenue.
The shifting insurance landscape may change broker commissions. But at Aflac, it's for the better. Guaranteed-issue group products, commissions and service. It may be more than you expect, but with Aflac anything is possible. Learn more at aflac.com/brokers.
Advertisement

  Industry Report 
  • Varian enters product marketing deal with Siemens
    Varian Medical Systems and Siemens Healthcare have entered a marketing partnership targeting the global radiation oncology market. Under the deal, Varian will represent Siemens' products for diagnostic imaging, including PET/CT, to international radiation oncology sites. Siemens will also represent Varian's radiosurgery and radiotherapy software and devices to its clients. AuntMinnie.com (free registration) (4/25) LinkedInFacebookTwitterEmail this Story
Making Work-Life Balance Work
For startups or established enterprises, juggling the demands of work and the rest of your day means knowing what's important, setting boundaries and getting creative. Click here to read Boomtown: Think Like a Startup
Advertisement

  News from the Field 
  • Microfluidic device can extract CTCs from blood samples
    Researchers from Harvard University and Children's Hospital Boston have developed a device for extracting circulating tumor cells from blood. Tests on mice with breast cancer showed the microfluidic device can catch more than 90% of the cancerous cells and keep them intact for culturing, according to findings published in the journal Lab on a Chip. The device has other potential uses, such as in gathering stem cells from blood. CNET/Cutting Edge blog (4/25) LinkedInFacebookTwitterEmail this Story
  Featured Content 
 

  International Developments 
  • Australian hospital opens PET research center
    The Austin Hospital in Victoria, Australia, is unveiling its Positron Emission Tomography Solid Targetry Laboratory, which will focus on nuclear medical imaging and research in cancer, neurology and cardiology. The center is considered the first of its kind in the country. Heidelberg Leader (Australia) (4/26) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • FDA user fee reauthorization faces obstacles
    Differences between House and Senate versions of bills reauthorizing the FDA Prescription Drug User Fee Act could delay the bill's progress. Differences include terms for exclusivity periods for new antibiotics, the FDA's mission and guidelines for how the agency determines devices' risks. Politico (Washington, D.C.) (4/25) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  From SNM 
  • The proven performance booster: "Steves' Review of Nuclear Medicine Technology"
    Get instant access to 200 self-evaluation questions, plus essential content on CT and PET in the new Steves' Review of Nuclear Medicine Technology, 4th edition. This detailed overview of nuclear medicine technology — updated and expanded to cover patient care, instrumentation, nuclear oncology, electrocardiography, interventional drugs and new therapeutic agents — is complemented by hundreds of self-evaluation questions and answers mirroring the structure of national certification examinations. Learn more. LinkedInFacebookTwitterEmail this Story
SNM  |  Molecular Imaging Community  |  SNM Annual Meeting  |  SNM Learning Center

News  |  SNM on Facebook  |  SNM Channel on YouTube  |  SNM's Virtual March for Health

  SmartQuote 
One person with a belief is equal to a force of 99 who have only interests."
--John Stuart Mill,
British philosopher and political economist


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent SNM SmartBrief Issues:   Lead Editor:  Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information